ReviewDisease markers2013
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.
Review in Disease markers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Multiple sclerosis clinical decision support system based on projection to reference datasets.Annals of clinical and translational neurology · 2022Trial
- Serum Levels of miR-34a-5p, miR-30b-5p, and miR-140-5p Are Associated with Disease Activity and Brain Atrophy in Early Multiple Sclerosis.International journal of molecular sciences · 2025Article
- Refining Prognostic Factors in Adult-Onset Multiple Sclerosis: A Narrative Review of Current Insights.International journal of molecular sciences · 2025Review
- Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.Journal of neurology · 2025Article
- Evaluation of Disease Modifying Therapies and Prognostic Factors Affecting Multiple Sclerosis Progression in a Local Centre of Hong Kong.Pragmatic and observational research · 2025Article
- Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis.Brain communications · 2025Article
- Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.Journal of neurology · 2024Review
- Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.Journal of neurology · 2024Article
- Article
- Predictors of long-term disability in multiple sclerosis patients using routine magnetic resonance imaging data: A 15-year retrospective study.The neuroradiology journal · 2023Article
- Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis.Therapeutic advances in neurological disorders · 2023Article
- Experimental and Clinical Biomarkers for Progressive Evaluation of Neuropathology and Therapeutic Interventions for Acute and Chronic Neurological Disorders.International journal of molecular sciences · 2022Review
- Basic Analysis of the Cerebrospinal Fluid: An Important Framework for Laboratory Diagnostics of the Impairment of the Central Nervous System.Current issues in molecular biology · 2022Article
- Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsing-remitting multiple sclerosis differently in female and male patients.Acta neurologica Belgica · 2021Article
- The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI.Journal of neurology · 2021Article
- A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.Journal of neurology · 2021Review
- The Evolution of Neurofilament Light Chain in Multiple Sclerosis.Frontiers in neuroscience · 2021Review
- Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance.Journal of neurology · 2020Article
- Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis.BMC neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) in which the complex interplay between inflammation and neurodegeneration determines varying degrees of neurological disability. For this reason, it is very difficult to express an accurate prognosis based on purely clinical information in the individual patient at an early disease stage. Magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers are promising sources of prognostic information with a good potential of quantitative measure, sensitivity, and reliability. However, a comprehensive MS outcome prediction model combining multiple parameters is still lacking. Current relevant literature addressing the topic of clinical, MRI, and CSF markers as predictors of MS disability progression is reviewed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.